Oncology Treatments

Crescent, Kelun-Biotech Trade Cancer Asset Rights in Cross-Border Deal as Crescent Secures $185 Million

The rights exchange sets 2026 clinical launches under a split granting Kelun CR-001 in Greater China, leaving SKB105 to Crescent outside China.